{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:52:59Z","timestamp":1791204779958,"version":"4.2.0"},"reference-count":51,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell therapy has transformed outcomes for children and young adults with relapsed\/refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL), enabling deep remissions even in patients who are refractory to chemotherapy or have relapsed after hematopoietic stem cell transplantation (HSCT). Use of adoptive cellular immunotherapy requires a strict clinical pathway and is delivered at designated CART-cell centers. Initial complete remission rates are high and often MRD (minimal residual disease)-negative, but relapse remains frequent through loss of persistence or antigen escape. Key acute toxicities are cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS), whereas longer-term issues include prolonged cytopenias, infection risk, B-cell aplasia, and hypogammaglobulinemia requiring immunoglobulin replacement. This narrative review for general pediatricians reviews the current state-of-the-art of CART-cell therapy for ALL and summarizes key principles about CART-cell indications, production, outcomes, complications, and relevant issues for shared-care centers on follow-up in the short and long term.<\/jats:p>","DOI":"10.1542\/peds.2026-076924","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:02:37Z","timestamp":1788998557000},"source":"Crossref","is-referenced-by-count":0,"title":["CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians"],"prefix":"10.1542","volume":"158","author":[{"given":"Antonio","family":"Grasso","sequence":"first","affiliation":[{"name":"1Department of Bone Marrow Transplantation, Great Ormond Street Children\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijeet K.","family":"Mishra","sequence":"additional","affiliation":[{"name":"2Cancer and Blood Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Silva","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation, Great Ormond Street Children\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persis J.","family":"Amrolia","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation, Great Ormond Street Children\u2019s Hospital, London, United Kingdom"},{"name":"2Cancer and Blood Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"},{"name":"3Molecular and Cellular Immunology Section, University College London Great Ormond Street Institute of Child Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"16","key":"2026100508123345900_r1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med."},{"issue":"9","key":"2026100508123345900_r2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA."},{"issue":"9","key":"2026100508123345900_r3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA."},{"issue":"5","key":"2026100508123345900_r4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"9967","key":"2026100508123345900_r5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"issue":"25","key":"2026100508123345900_r6","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood."},{"issue":"26","key":"2026100508123345900_r7","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood."},{"issue":"9","key":"2026100508123345900_r8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"2026100508123345900_r9","volume-title":"Kymriah (tisagenlecleucel) [package insert]","year":"2025"},{"issue":"16","key":"2026100508123345900_r10","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/JCO.2024.42.16_suppl.10016","article-title":"Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results","volume":"42","author":"Rouce","year":"2024","journal-title":"J Clin Oncol."},{"issue":"11","key":"2026100508123345900_r11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"7","key":"2026100508123345900_r12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/archdischild-2024-328263","article-title":"Chimeric antigen receptor T cell therapy in childhood leukaemia","volume":"110","author":"Wang","year":"2025","journal-title":"Arch Dis Child."},{"key":"2026100508123345900_r13","article-title":"Foundation for the Accreditation of Cellular Therapy"},{"issue":"11","key":"2026100508123345900_r14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jtct.2023.08.030","article-title":"INSPIRED symposium part 2: prevention and management of relapse following chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia","volume":"29","author":"Lamble","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"2026100508123345900_r15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"issue":"2","key":"2026100508123345900_r16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"issue":"1","key":"2026100508123345900_r17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2026100508123345900_r18","doi-asserted-by":"crossref","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol."},{"issue":"6","key":"2026100508123345900_r19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.hoc.2023.06.003","article-title":"The current state of chimeric antigen receptor T cell therapy for B lymphoblastic leukemia","volume":"37","author":"McClory","year":"2023","journal-title":"Hematol Oncol Clin North Am."},{"issue":"2","key":"2026100508123345900_r20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther."},{"issue":"16","key":"2026100508123345900_r21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"issue":"9","key":"2026100508123345900_r22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med."},{"issue":"7","key":"2026100508123345900_r23","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"issue":"2","key":"2026100508123345900_r24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J Clin Oncol."},{"issue":"21","key":"2026100508123345900_r25","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"issue":"14","key":"2026100508123345900_r26","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR\u00a0T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood."},{"issue":"10","key":"2026100508123345900_r27","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol."},{"key":"2026100508123345900_r28","article-title":"National Comprehensive Cancer Network"},{"issue":"1","key":"2026100508123345900_r29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"9","key":"2026100508123345900_r30","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol."},{"issue":"6","key":"2026100508123345900_r31","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"11","key":"2026100508123345900_r32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv."},{"issue":"27","key":"2026100508123345900_r33","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol."},{"issue":"9","key":"2026100508123345900_r34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med."},{"issue":"6","key":"2026100508123345900_r35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr Opin Hematol."},{"issue":"15","key":"2026100508123345900_r36","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol."},{"issue":"4","key":"2026100508123345900_r37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"20","key":"2026100508123345900_r38","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood."},{"key":"2026100508123345900_r39","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric antigen receptor t cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front Immunol."},{"issue":"13","key":"2026100508123345900_r40","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","article-title":"Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults","volume":"8","author":"Lamble","year":"2024","journal-title":"Blood Adv."},{"issue":"suppl 1","key":"2026100508123345900_r41","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis."},{"issue":"12","key":"2026100508123345900_r42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr."},{"issue":"8","key":"2026100508123345900_r43","first-page":"971","article-title":"Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a U.S. hospital\u2019s perspective","volume":"26","author":"Yang","year":"2020","journal-title":"J Manag Care Spec Pharm."},{"issue":"22","key":"2026100508123345900_r44","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA."},{"issue":"11","key":"2026100508123345900_r45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"7","key":"2026100508123345900_r46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst."},{"issue":"9","key":"2026100508123345900_r47","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jcyt.2023.05.011","article-title":"A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R\/R B-ALL) treatment in children and young adults","volume":"25","author":"Andrade","year":"2023","journal-title":"Cytotherapy."},{"issue":"4","key":"2026100508123345900_r48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma","volume":"9","author":"de Oliveira Canedo","year":"2025","journal-title":"Blood Adv."},{"issue":"10","key":"2026100508123345900_r49","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jtct.2023.07.009","article-title":"Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium","volume":"29","author":"Schultz","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"4","key":"2026100508123345900_r50","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41591-026-04296-8","article-title":"Engineering in vivo CAR-T cells","volume":"32","author":"Greco","year":"2026","journal-title":"Nat Med."},{"issue":"1","key":"2026100508123345900_r51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-076924\/1958889\/pediatrics.2026076924.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-076924\/1958889\/pediatrics.2026076924.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:12:45Z","timestamp":1791202365000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/4\/e2026076924\/208850\/CART-Cell-Therapy-in-Pediatric-Acute-Lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-076924","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"e2026076924"}}